Fusilev

Fusilev is a brand name of levoleucovorin calcium, approved by the FDA in the following formulation(s):

FUSILEV (levoleucovorin calcium - powder; iv (infusion))

• 
  Manufacturer: SPECTRUM PHARMS
  
  Approval date: March 7, 2008
  
  Strength(s): EQ 50MG BASE/VIAL ^[RLD]

FUSILEV (levoleucovorin calcium - solution; iv (infusion))

• 
  Manufacturer: SPECTRUM PHARMS
  
  Approval date: April 29, 2011
  
  Strength(s): EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML) ^[RLD], EQ 250MG BASE/25ML (EQ 10MG BASE/ML) ^[RLD]

Has a generic version of Fusilev been approved?

No. There is currently no therapeutically equivalent version of Fusilev available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Fusilev. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Substantially pure diastereoisomers of tetrahydrofolate derivatives
  Patent 6,500,829
  Issued: December 31, 2002
  Inventor(s): Hamish Christopher Swan; Wood & Colin James; Suckling & Lilias G.; Rees
  Assignee(s): University of Strathclyde
  The present invention related to the preparation of substantially pure diastereoisomers of derivatives of tetrahydrofolate and the use of such diastereoisomers. More particularly the present invention provides a process for the preparation of a desired substantially pure (6R or 6S) diastereoisomer of a derivative of tetrahydrofolic acid or salt or ester. The process comprises the steps of: attaching a chiral auxiliary group at either N-5 or N-10 of a mixture of 6R and 6S diastereoisomers of tetrahydrofolic acid, separating the new diastereoisomers, recovering the desired new diastereoisomer (6R or 6S) corresponding to the desired (6R or 6S) diastereoisomer, and converting the substantially pure new diastereoisomer recovered into the corresponding diastereoisomer.
  
  Patent expiration dates:
  
  
  • December 31, 2019
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • March 7, 2011 - NEW PRODUCT
  
  
  • April 29, 2014 - USE IN COMBINATION CHEMOTHERAPY WITH 5-FLUOROURACIL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED METASTATIC COLORECTAL CANCER
  
  
  • March 7, 2015 - ORPHAN DRUG EXCLUSIVITY
  
  
  • April 29, 2018 - ORPHAN DRUG EXCLUSIVITY
  
  

See also...

• Fusilev Consumer Information (Wolters Kluwer)
• Fusilev Consumer Information (Cerner Multum)
• Fusilev Advanced Consumer Information (Micromedex)
• Fusilev AHFS DI Monographs (ASHP)
• Levoleucovorin Consumer Information (Drugs.com)
• Levoleucovorin Calcium Consumer Information (Wolters Kluwer)
• Levoleucovorin 1 Consumer Information (Cerner Multum)
• Levoleucovorin Consumer Information (Cerner Multum)
• Levoleucovorin Intravenous Advanced Consumer Information (Micromedex)
• Levoleucovorin Calcium AHFS DI Monographs (ASHP)